Tackling stability issues in cell therapy and antibody development

We sat down with Christopher Bravery, Director of Consulting at Advanced Biologicals, to discuss stability issues and how they differ between cell therapy development and antibody development, analytical methods for cell therapy development, and what is still needed in terms of stability.

"There is a myriad of issues around cell therapy and you have two basic choices to make in early development; will I provide this as a fresh product or a cryopreserved product? There are pros and cons to both, so what does the future hold in terms of development in order to make a huge difference in commercialization?"

Watch the interview below to hear what Bravery has to say on these topics and many more.